IMAPAC Market Intelligence’s Post

According to Pharmaceutical-Technology, it's the era of ADCs, and we're not sad about it! https://lnkd.in/d7N6cAY7 Antibody drug conjugates (ADCs) dominate the oncology clinical research and dealmaking landscape. But how are biotechs differentiating themselves in a buzzing market? By using different targets and newer engineering methods. But not all providers can support these new strategies and methodologies! At Veloxity Labs, LLC, we provide our clients an innovative workflow that results in a rapid plug-and-play bioanalytical solution for the quantitation of monoclonal antibodies (mAbs) and ADCs. Leave a comment below or email us at info@veloxitylabs.com to learn how we can get your studies up and running quickly with fast turnaround times, high-quality data and more. #Bioanalysis #LCMS #GLP #Innovation #Scalability #CRO #VeloxityLabs

To all of you attending Biologics 2024 next week, I look forward to presenting an update of the Antibodies to Watch series and a preview of The Antibody Society in-depth analyses of success rates and clinical development phase lengths for antibody therapeutics! #Biologics24 #mabs #antibodydiscovery #antibodydevelopement #antibodyengineering

Publication Spotlight: "Further Accelerating Biologics Development from DNA to IND: The Journey from COVID-19 to Non-COVID-19 Programs, Antibody Therapeutics." In this newly published review, the post-pandemic outlook of biologics development is discussed, with exclusive experience sharing and insights from WuXi Biologics. Here are what you can gain from the paper: - Acceleration strategies employed by biopharmaceutical companies worldwide during COVID-19 - WuXi Biologics’ strategies and experience in the accelerated development of more than 30 COVID-19 antibodies - WuXi Biologics’ insights and success in applying accelerated strategies in more than 30 non-COVID-19 programs - How a generic 6-month DNA-to-IND timeline is achievable for general biologics development At WuXi Biologics, we strive to continuously improve and advance the science and technologies involved in the discovery, development, and manufacturing of biologics and vaccines. To read the full paper, please visit: https://lnkd.in/eXm8iZH9 #research #science #innovation #biopharma #biotherapeutics #bioprocessing #biomanufacturing #discovery #drugdiscovery #drugdevelopment #publication

#Biologics_and_Biosimilars Market is estimated to grow at a high CAGR >> https://lnkd.in/d_qE6FKe #Biologics are therapeutic #agents sourced from #living #organisms, such as #proteins, nucleic #acids, and #cells, used to treat various #medical conditions, including #autoimmune disorders, cancer, and #chronic #diseases. Biologics and #biosimilars are characterized by their #complexity and #production through #biotechnological methods. Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Company, Novartis, Merck, Biotech, Innovent Biologics #biologics #therapeuticagents #biosimilars #livingorganisms #biotechnology #pharmaceutical #medicaldevices #medicaltechnologies #healthcareindustry #medicalscience

Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/gqUmsnFC #Chemenu #biopharmaceutical #R&Dpipelines #camizestrant #SERD #Erα #anti-cancer #ER-activating mutations #drugdiscovery #buildingblocks

Thoughts on this? >> Merck pays $700M for clinical-stage CD3xCD19 bispecific antibody >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharma #pharmaceutical

🔬 Pfizer's strategic shift towards biologics in oncology reveals a nuanced response to healthcare legislation! 💊💡 With the Inflation Reduction Act (IRA) influencing drug pricing, Pfizer adapts its portfolio mix for a more sustainable future. 📉📊 #Pfizer #Biologics #HealthcareLegislation Under IRA provisions, biologics enjoy a longer grace period post-approval, impacting Pfizer's focus on antibody-drug conjugates (ADCs) and bispecific antibodies. 🕰️🛠️ By 2030, biologics are expected to contribute 65% to Pfizer's oncology revenues. 📈💰 This strategic pivot reflects industry-wide concerns about small molecule R&D, particularly in oncology. 💔💉 Pfizer's emphasis on ADCs post-Seagen acquisition showcases a commitment to innovation in cancer therapy. 🌟🩺 #ADC #CancerResearch #Biotech By leveraging expertise from Seagen, Pfizer aims to pioneer next-generation cancer therapies, combining protein engineering with ADC technology. 🧬💼 The goal? At least eight potential blockbuster assets by 2030. 💥🎯 #Innovation #Research #HealthcareFuture Pfizer's game plan underscores the dynamic interplay between legislation, innovation, and strategic investment in healthcare. 💡🔄 Stay tuned as the industry navigates these evolving landscapes! 🚀🌐 #HealthcareTrends #Biopharma #StrategicShift

Thoughts on this? >> Merck pays $700M for clinical-stage CD3xCD19 bispecific antibody >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical

mRNA Characterization - from 5’ cap to poly (A): what IPRP-LC–MS can tell you #mRNA is a biotherapeutic modality primarily used in #vaccines and undergoes a complex manufacturing process involving #invitrotranscription. In order to ensure the desired product quality of mRNA therapeutics, critical quality attributes must be maintained within appropriate limits. Therefore, the implementation of robust analytical methods is crucial for making quality decisions. Next month, join Phenomenex’s Roxana Eggleston-Rangel (Advanced Workflows Applications Manager, Pharma & Biopharma) as she introduces a novel #mRNAcharacterization workflow that yields mRNA molecules exceeding 1,000 nucleotides in length, with a 5' cap and a poly (A) tail Register for this #webinar below:

In her recent interview with pharmaphorum, a leading media platform dedicated to pharmaceutical and biotech innovation, Annette Bakker, CEO of the Children’s Tumor Foundation, shared how drug repositioning is making a real difference for NF patients. This approach delivers more "shots on goal" by finding new uses for existing drugs, bringing treatments to patients faster and more efficiently. At CTF, we're committed to exploring every opportunity - whether repositioning existing compounds or developing new drugs = to expand treatment options and improve lives for those living with any form of NF. More treatments, faster, and always focused on better outcomes for patients. Click to read the entire interview. https://lnkd.in/eN9SQdKN #EndNF #makeNFvisible